Bayer Faces 67,000 Lawsuits and $20 Billion Verdict as Legal Storm Intensifies

German chemical and pharmaceutical conglomerate Bayer is facing escalating legal pressure in the United States over its controversial herbicide glyphosate, sold under the brand Roundup. With over 67,000 lawsuits still pending, Bayer is now aggressively seeking a comprehensive out-of-court settlement in Missouri state court. Insiders report that if this settlement fails, the company may pivot to a radical legal strategy: having its U.S. subsidiary Monsanto file for Chapter 11 bankruptcy, a move that would shield it from most pending claims.

Bayer’s $63 billion acquisition of Monsanto in 2018 was meant to boost its global presence in agricultural science. Instead, it opened a floodgate of litigation linked to glyphosate’s alleged cancer risks. While Bayer and global regulators continue to deny any carcinogenic connection, juries across the U.S. have increasingly sided with plaintiffs. One recent case in Georgia awarded over $2 billion in damages, triggering deep concern among investors.

So far, Bayer has paid around $10 billion in settlements and reserved another $5.9 billion for future payouts. Although it has resolved two-thirds of the lawsuits, the scale of unresolved claims remains daunting. The legal epicenter is Missouri, where Bayer is racing against time to avoid what some analysts call a “legal reckoning.”

Bayer has engaged Latham & Watkins and AlixPartners to evaluate bankruptcy as a risk mitigation strategy. Chapter 11 would offer temporary relief from liabilities—but at a steep reputational and legal cost. Critics argue this tactic could ignite new rounds of litigation while undermining public trust.

Market reactions have been volatile. News of a potential settlement briefly pushed Bayer’s shares up 2.4%, only to plummet 10% after U.S. Health Secretary Robert F. Kennedy Jr. announced plans to label glyphosate as a potential health risk, with a report due on May 22.

Adding to the challenge, Bayer’s market value has plunged from €100 billion in 2018 to just €25 billion today. The financial and reputational fallout from the Monsanto acquisition has fundamentally reshaped the company. Still, Bayer insists glyphosate is safe, citing studies from the EPA and EU regulators.

Back in Germany, Bayer is moving ahead with long-term strategic investments, including land acquisitions and property divestments in Wuppertal, where it plans to expand operations and exit the local housing market.

With legal and financial pressure mounting, Bayer now stands at a critical crossroads. A nationwide settlement could ease its legal burden, but if glyphosate is banned or heavily restricted in the U.S., Bayer may need to revamp its agricultural strategy entirely. The consequences of a single mega-acquisition continue to ripple through every corner of the company’s future.